1. Effect of pembrolizumab on CD4+CD25+, CD4+LAP+ and CD4+TIM‐3+ T cell subsets. (17th February 2019) Authors: Toor, S. M.; Sasidharan Nair, V.; Pfister, G.; Elkord, E. Journal: Clinical and experimental immunology Issue: Volume 196:Number 3(2019) Page Start: 345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. In‐vitro effect of pembrolizumab on different T regulatory cell subsets. (3rd November 2017) Authors: Toor, S. M.; Syed Khaja, A. S.; Alkurd, I.; Elkord, E. Journal: Clinical and experimental immunology Issue: Volume 191:Number 2(2018:Feb.) Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗